6-溴-3,4-二氢螺[苯并[b][1,4]噁嗪-2,1-环丙烷] | 1291094-46-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 中文名称: 6-溴-3,4-二氢螺[苯并[b][1,4]噁嗪-2,1-环丙烷]
• 英文名称: 6-bromo-3,4-dihydrospiro[benzo[b][1,4]oxazine-2,1'-cyclopropane]
• 英文别名: 6-bromospiro[3,4-dihydro-1,4-benzoxazine-2,1'-cyclopropane]
• CAS: 1291094-46-6
• 化学式: C₁₀H₁₀BrNO
• 分子量: 240.099
• InChiKey: MEKWQPBFYRGZDS-UHFFFAOYSA-N

物化性质

• 沸点：
  341.0±42.0 °C(Predicted)
• 密度：
  1.65±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  6-溴-3,4-二氢螺[苯并[b][1,4]噁嗪-2,1-环丙烷] 在 三乙基硅烷 、 正丁基锂 、 三氟甲磺酸 、 potassium carbonate 、 三氟乙酸 作用下， 以 四氢呋喃 、 正己烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.25h， 生成 4-benzyl-6-[(5-bromo-2-chloro-phenyl)methyl]spiro[3H-1,4-benzoxazine-2,1'-cyclopropane]
  参考文献：
  名称：

  [EN] GLYCOSIDE DERIVATIVES AND USES THEREOF
  [FR] DÉRIVÉS DE GLYCOSIDE ET UTILISATIONS DE CEUX-CI

  摘要：

  这项发明涉及由式(I)表示的化合物，其中变量如上所定义，这些化合物对治疗由钠D-葡萄糖共转运蛋白（SGLT）介导的疾病和症状，例如糖尿病，具有益处。该发明还提供了治疗这些疾病和症状的方法，以及用于治疗的组合物等。

  公开号：

  WO2011048112A1
• 作为产物：
  描述：

  6-bromospiro([2H][1,4]benzoxazine-2,1'-cyclopropane)-3(4H)-one 在 borane tetrahydrofuran 、 甲醇 、 乙酸乙酯 、 碳酸氢钠 、 Brine 、 Sodium sulfate-III 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以to yield 6-bromo-3,4-dihydrospiro[benzo[b][1,4]oxazine-2,1′-cyclopropane] 7.23 (127 mg), which的产率得到6-溴-3,4-二氢螺[苯并[b][1,4]噁嗪-2,1-环丙烷]
  参考文献：
  名称：

  Substituted pyrrolidines as SYK inhibitors

  摘要：

  本公开涉及的化合物是Syk抑制剂，用于治疗各种疾病状态，包括癌症和炎症疾病。在特定实施例中，化合物的结构由公式I给出：其中X1、X2、X3、R2、R3、R4、R5和Y如本文所述。本公开还提供了含有公式I的化合物或其药学上可接受的盐的药物组合物，以及使用这些化合物和组合物治疗由Syk介导的疾病状态的方法。

  公开号：

  US09376441B2

文献信息

• Syk 억제제
  申请人：GILEAD SCIENCES, INC. 길리애드 사이언시즈, 인코포레이티드(519990290219)

  公开号：KR20160037198A

  公开（公告）日：2016-04-05

  본 개시내용은 Syk 억제제인 화합물, 및 암 및 염증성 상태를 비롯한 다양한 질환 상태의 치료에서의 그의 용도에 관한 것이다. 특정한 실시양태에서, 화합물의 구조는 하기 화학식 I로 주어진다. 003c#화학식 I003e# 상기 식에서, X, X, X, R, R, R, R, 및 Y는 본원에 기재된 바와 같다. 본 개시내용은 화학식 I의 화합물 또는 그의 제약상 허용되는 염을 포함하는 제약 조성물, 및 Syk에 의해 매개되는 상태를 치료하기 위해 이들 화합물 및 조성물을 사용하는 방법을 추가로 제공한다.

  This text appears to be a scientific or technical document discussing the therapeutic uses of a compound called Syk inhibitor in the treatment of various conditions including cancer and inflammatory diseases. It also mentions the chemical structure of the compound given by the chemical formula I. In the formula, X, X, X, R, R, R, R, and Y are as described in the specification. The document further provides methods for using these compounds and compositions containing compounds or salts thereof of the chemical formula I to treat conditions mediated by Syk.
• Glycoside Derivatives and Uses Thereof
  申请人：BEBERNITZ Gregory Raymond

  公开号：US20110171159A1

  公开（公告）日：2011-07-14

  This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.

  这项发明涉及由式(I)表示的化合物：其中变量如上所定义，这些化合物对治疗由钠D-葡萄糖共转运蛋白（SGLT）介导的疾病和症状，例如糖尿病，具有用处。该发明还提供了治疗这些疾病和症状的方法，以及用于治疗的组合物等。
• Glycoside derivatives and uses thereof
  申请人：Novartis AG

  公开号：US08163704B2

  公开（公告）日：2012-04-24

  This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.

  本发明涉及由公式(I)表示的化合物：其中变量如上所述，这些化合物对于治疗通过钠D-葡萄糖共转运体（SGLT）介导的疾病和症状如糖尿病等是有用的。本发明还提供了治疗这些疾病和症状的方法、组合物等。
• GLYCOSIDE DERIVATIVES AND USES THEREOF
  申请人：BEBERNITZ Gregory Raymond

  公开号：US20120178680A1

  公开（公告）日：2012-07-12

  This invention relates to compounds represented by formula (I): wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes. The invention also provides methods of treating such diseases and conditions, and compositions etc. for their treatment.

  本发明涉及由式(I)所表示的化合物：其中变量的定义如上所述，这些化合物对于治疗由钠D-葡萄糖共转运体（SGLT）介导的疾病和病状，例如糖尿病，是有用的。本发明还提供了治疗这些疾病和病状的方法、组合物等。
• SYK INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20150038488A1

  公开（公告）日：2015-02-05

  The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I wherein X 1 , X 2 , X 3 , R 2 , R 3 , R 4 , R 5 , and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

  本公开涉及的化合物是Syk抑制剂，并且适用于治疗各种疾病状态，包括癌症和炎症性疾病。在特定实施例中，化合物的结构由公式I给出，其中X1、X2、X3、R2、R3、R4、R5和Y如本文所述。本公开进一步提供了包括公式I的化合物或其药学上可接受的盐的制药组合物，以及使用这些化合物和组合物治疗Syk介导的疾病的方法。